12-Month Outcomes of Combined Phacoemulsification and iStent Inject in Asian Eyes with Normal Tension Glaucoma: A Single-Centre Experience.
Asian
Glaucoma
Minimally invasive glaucoma surgery
Normal tension glaucoma
iStent inject
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
13
02
2021
accepted:
22
09
2021
pubmed:
16
10
2021
medline:
3
3
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
To evaluate efficacy and safety of the iStent inject combined with phacoemulsification in Asian eyes with normal-tension glaucoma (NTG) up to 12 months after surgery. Retrospective case series. Retrospective case series of eyes undergoing surgery from April 2017 to August 2019. Outcome measures included intraocular pressure (IOP), number of topical glaucoma medications and adverse outcomes. Data were retrieved from the post-operative day 1 (POD1), week 1 (POW1), month 1 (POM1), month 3 (POM3), month 6 (POM6) and month 12 (POM12) timepoints. Data were analysed at each timepoint for eyes with available clinical data at that visit. Subgroup analysis was performed for a consistent cohort which included only eyes with data at all six follow-up timepoints. Data from 91 eyes in the collective subject group was analysed. Majority of subjects were male (53, 58.2%) and Chinese (79, 86.8%). Mean age was 73.2 ± 7.2 years. Pre-operatively, mean IOP was 14.3 ± 3.0 mmHg and mean number of medications was 1.5 ± 0.8. Significant IOP reduction was observed at all timepoints except POW1 and POM12. The number of medications was reduced at all timepoints (p < 0.001). By POM12, there was reduction of 1.2 ± 1.0 medications (p < 0.001). Both the collective and consistent cohorts demonstrated a trend towards decreasing surgical efficacy with time, in IOP reduction and decrease in medications. None of the eyes experienced sight-threatening complications. Asian eyes with NTG undergoing combined phacoemulsification and iStent inject surgery demonstrated significant and sustained reduction in number of glaucoma medications up to 12 months post-operatively.
Identifiants
pubmed: 34652545
doi: 10.1007/s10792-021-02033-3
pii: 10.1007/s10792-021-02033-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
611-620Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90(3):262–267
doi: 10.1136/bjo.2005.081224
Lee WYJ, Chan PP, Zhang XJ, Chen LJ, Jonas JB (2019) Latest developments in normal-pressure glaucoma: diagnosis, epidemiology, genetics, etiology, causes abd mechanisms to management. Asia Pac J Ophthalmol (Phila) 8:457–468
doi: 10.1097/01.APO.0000605096.48529.9c
Wang NL, Friedman DS, Zhou Q, Guo L, Zhu D, Peng Y et al (2011) A population-based assessment of 24-hour intraocular pressure among subjects with primary open-angle glaucoma: the handan eye study. Invest Ophthalmol Vis Sci 52:7817–7821
doi: 10.1167/iovs.11-7528
Zhao J, Solano MM, Oldenburg CE, Liu T, Wang Y, Wang N et al (2019) Prevalence of normal-tension glaucoma in the Chinese population: a systematic review and meta-analysis. Am J Ophthalmol 199:101–110
doi: 10.1016/j.ajo.2018.10.017
Cho HK, Kee C (2014) Population-based glaucoma prevalence studies in Asians. Surv Ophthalmol 59(4):434–447
doi: 10.1016/j.survophthal.2013.09.003
Jongsareejit B, Tomidokoro A, Mimura T, Tomita G, Shirato S, Araie M (2005) Efficacy and complications after trabeculectomy with mitomycin C in normal-tension glaucoma. Jpn J Ophthalmol 49(3):223–227
doi: 10.1007/s10384-004-0181-9
Membrey WL (2000) Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 Intraocular pressure control and complications. Br J Ophthalmol 84(6):586–590
doi: 10.1136/bjo.84.6.586
Saheb H, Ahmed IIK (2012) Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 23(2):96–104
doi: 10.1097/ICU.0b013e32834ff1e7
Fea AM, Belda JI, Rekas M, Junemann A, Chang L, Pablo L et al (2014) Prospective unmasked randomized evaluation of the iStent inject versus two ocular hypotensive agents in patients with primary open angle glaucoma. Clin Ophthalmol 8:875–882
pubmed: 24855336
pmcid: 4019628
Voskanyan L, Garcia-Feijoo J, Belda JI, Fea A, Junemann A, Baudouin C et al (2014) Prospective, unmasked evaluation of the iStent inject system for open-angle glaucoma: synergy trial. Adv Ther 31(2):189–201
doi: 10.1007/s12325-014-0095-y
Klamann MK, Gonnermann J, Pahlitzsch M, Maier AK, Joussen AM, Torun N et al (2015) iStent inject in phakic open angle glaucoma. Graefes Arch Clin Exp Ophthalmol 253(6):941–947
doi: 10.1007/s00417-015-3014-2
Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz- Valle D, Morales-Fernandez L, Fernandez-Perez C, Garcia-Feijoo J (2016) Glaukos iStent inject trabecular micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle glaucoma or ocular hypertension: a long-term study. J Ophthalmol 2016:1056573
pubmed: 27882243
pmcid: 5108856
Lindstrom R, Lewis R, Hornbeak DM, Voskanyan L, Giamporcaro JE, Hovanesian J et al (2016) Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication: 18-month follow-up. Adv Ther 33(11):2082–2090
doi: 10.1007/s12325-016-0420-8
Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I (2018) Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther 7(2):405–415
doi: 10.1007/s40123-018-0152-8
Guedes RAP, Gravina DM, Lake JC, Guedes VMP, Chaoubah A (2019) Intermediate results of iStent or iStent inject implantation combined with cataract surgery in a real-world setting: a longitudinal retrospective study. Ophthalmol Ther 8(1):87–100
doi: 10.1007/s40123-019-0166-x
Salimi A, Clement C, Shiu M, Harasymowycz P (2020) Second-Generation trabecular micro-bypass (iStent inject) with cataract surgery in eyes with normal-tension glaucoma: one-year outcomes of a multi-centre study. Ophthalmol Ther 9:585–596
doi: 10.1007/s40123-020-00266-6
Vlasov A, Kim WI (2017) The efficacy of two trabecular bypass stents compared to one in the management of open-angle glaucoma. Mil Med 182(S1):222–225
doi: 10.7205/MILMED-D-16-00135
Salimi A, Lapointe J, Harasymowycz P (2019) One-year outcomes of second-generation trabecular micro-bypass stents (iStent Inject) implantation with cataract surgery in different glaucoma subtypes and severities. Ophthalmol Ther 8(4):563–575
doi: 10.1007/s40123-019-00214-z
Clement CI, Howes F, Ioannidis AS, Shiu M, Manning D (2019) One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study. Clin Ophthalmol 13:491–499
doi: 10.2147/OPTH.S187272
Hooshmand J, Rothschild P, Allen P, Kerr NM, Vote BJ, Toh T (2019) Minimally invasive glaucoma surgery: comparison of iStent with iStent inject in primary open angle glaucoma. Clin Experiment Ophthalmol 47:898–903
doi: 10.1111/ceo.13526
Neuhann R, Neuhann T (2020) Second-generation trabecular micro-bypass stent implantation: retrospective analysis after 12- and 24-month follow-up. Eye Vis (Lond) 7:1
doi: 10.1186/s40662-019-0169-7
Lindstrom R, Sarkisian SR, Lewis R, Hovanesian J, Voskanyan L (2020) Four-year outcomes of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication. Clin Ophthalmol 14:71–80
doi: 10.2147/OPTH.S235293
Pillunat LE, Erb C, Jünemann AG, Kimmich F (2017) Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clin Ophthalmol 29(11):1583–1600
doi: 10.2147/OPTH.S135316
Lee RY, Chon BH, Lin SC, He M, Lin SC (2015) Association of ocular conditions with narrow angles in different ethnicities. Am J Ophthalmol 160(3):506-515.e1
doi: 10.1016/j.ajo.2015.06.002